Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-10-03 Regulatory Filings
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about an independent review committee's evaluation of interim clinical trial data and a recommendation to continue the trial without protocol changes. There are no financial statements or detailed financial data presented, only a summary of a clinical trial update and a press release attachment. The document length is 3073 characters, which is relatively short and consistent with an 8-K current report. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like earnings release, annual report, or management discussion. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability.
2019-10-03 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 4, 2019, reporting the resignation of the Chief Financial Officer and related management changes. The key section is Item 5.02, which specifically addresses departure and appointment of directors or officers. There is no financial data or report attached, nor is this an announcement of a report publication. The content focuses solely on management changes, fitting the Board/Management Information category.
2019-09-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2019, reporting the results of operations and financial condition for the quarter ended June 30, 2019. It references a press release announcing quarterly results (Exhibit 99.1). The text explicitly states that the press release is furnished as an exhibit and is not deemed filed for certain regulatory purposes. The document is short (3381 characters) and primarily serves as a current report to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document is best classified as an Earnings Release (ER).
2019-08-08 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-08 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by the company. It details the terms of the offering, including the number of shares, pricing, use of proceeds, and other offering-related information. It is not a financial report, earnings release, or management discussion, but rather a capital raising document describing a securities offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the correct classification is CAP with high confidence.
2019-06-13 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 12, 2019, by Spero Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a securities purchase agreement for a registered direct offering of common stock. The document includes details about the offering, purchase price, closing conditions, and related exhibits such as the purchase agreement and a press release. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The content focuses on a capital raising transaction and related disclosures. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length (7343 characters) supports it being a full filing rather than a brief announcement or certification. Confidence is high given the clear description of a financing transaction and the use of Form 8-K for such disclosures.
2019-06-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.